Ichnos Glenmark Innovation Information

At Ichnos Glenmark Innovation (IGI), our mission is to provide curative therapies that extend and improve lives. IGI is an alliance between Ichnos Sciences Inc., a global fully-integrated clinical-stage biotech company developing multispecifics™ in oncology, and its parent, Glenmark Pharmaceuticals Ltd. (Glenmark), with the aim to accelerate new drug discovery in cancer treatment. IGI combines Ichnos' research and development proficiencies in novel biologics with those of Glenmark’s in new small molecules to continue developing cutting-edge therapy solutions that treat hematological malignancies and solid tumors. Harnessing the combined proficiency of over 150 scientists and a robust pipeline of novel molecules, this collaboration will leverage the capabilities of its three global centers of innovation spread across the USA, Switzerland and India to propel Innovation. We believe in the power of collaboration to drive innovation. Being an alliance, we ourselves embody this belief. Collaboration that helps us combine forces of expertise, technology, speed and reach between Ichnos and Glenmark as well as among other stakeholders. Collaboration that helps us transform the world of oncology by creating novel cutting-edge therapeutics, faster. Collaboration that kindles new hope for oncology patients, their families and healthcare professionals.